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Background:  Acyclovir  (ACV)  is the  antiviral  drug  of choice  to treat  patients  with  herpes  simplex  virus
type  1 (HSV-1)  uveitis.  The  prevalence  of intra-ocular  ACV-resistant  (ACVR) HSV-1  in  herpetic  uveitis  is
unknown  and may  have clinical  consequences.  In  addition  to its predictive  value  on  ACV  susceptibility,
the  polymorphic  HSV-1  thymidine  kinase  (TK) gene  facilitates  differentiation  between  HSV-1  strains.
Objectives:  The  objective  of  this  study  was  to  determine  the  genetic  composition  and  ACV susceptibility
of  the  causative  virus  in intra-ocular  ﬂuid samples  (IOF)  of HSV-1  uveitis  patients.
Study design:  The intra-ocular  HSV-1  pool  from  11  HSV-1  uveitis  patients  was  determined  by  sequencing
IOF-derived  viral  TK  genes.  The  ACV  susceptibility  proﬁle  of  the  cloned  intra-ocular  TK variants  was
deﬁned  by mass  spectrometry.  In addition,  the  ganciclovir  (GCV)  susceptibility  of the  ACVR HSV-1  TK
variants  was  deﬁned.
Results: Intra-ocular  ﬂuid  samples  of HSV-1  uveitis  patients  contain  HSV-1  quasispecies,  principally  con-
sisting  of one  major  and  multiple  genetically  related  minor  patient-speciﬁc  TK  variants.  Four  of  10  patients
R Ranalyzed  had  an intra-ocular  ACV HSV-1  of  which  3 were  cross-resistant  to  GCV.  The  ACV proﬁle  of
intra-ocular  HSV-1  did  not correlate  with  symptomatic  ACV  treatment.
Conclusions:  Affected  eyes  of HSV-1  uveitis  patients  are  commonly  infected  with  a patient-speciﬁc  HSV-
1 quasispecies,  including  one  major  and  multiple  genetically  related  minor  variants.  A relatively  high
prevalence  of intra-ocular  ACVR HSV-1,  mainly  ACV/GCV  cross-resistant  viruses,  was  detected  in  HSV-1
uveitis  patients.. Background
Herpes simplex virus type 1 (HSV-1) is an endemic human
lphaherpesvirus that causes a variety of diseases, including the
ight-threatening ocular diseases keratitis and uveitis.1,2 HSV-1
stablishes a lifelong latent infection in sensory neurons that inner-
ate the site of primary infection and reactivates intermittently to
ause recrudescent disease.1
HSV-1 uveitis is due to an initial cytopathic effect of the virus
n uveal-resident cells followed by a local inﬂammatory response
Abbreviations: HSV-1, herpes simplex virus type 1; IOF, intra-ocular ﬂuid; TK,
hymidine kinase; ACV, acyclovir; GCV, ganciclovir; TG, trigeminal ganglion.
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to the inciting virus. Treatment is therefore aimed at inhibiting
viral replication with antiviral drugs and dampening the intra-
ocular immune response with anti-inﬂammatory agents.2 The
antiviral drug acyclovir (ACV), highly selective for human alpha-
herpesviruses and low in cytotoxicity, is the gold standard to
treat HSV-1 uveitis. Acyclovir is converted to ACV-monophosphate
(ACVmp) by virus-encoded thymidine kinase (TK) protein, which
is subsequently converted by cellular enzymes to the active com-
pound ACV-triphosphate that inhibits viral replication.3,4 ACV can
be applied topically and systemically and is given as prophylaxis to
prevent recurrent ocular HSV-1 diseases.5
The prevalence of ACV resistant (ACVR) HSV-1 is generally
low for immunocompetent individuals (<1%), but higher in the
Open access under the Elsevier OA license.immunocompromised (4–14%).3,6–8 This difference illustrates the
pivotal role of the host’s immune system to control HSV-1
infections.4 Recently, we reported on the relatively high incidence
of ACVR HSV-1 in otherwise healthy HSV-1 keratitis patients.7
2  Clinic
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otably, patients with corneal ACVR HSV-1 were refractory to ACV
herapy and had poor visual outcome.7,9 Resistance to ACV is com-
only due to speciﬁc mutations in the viral TK and incidentally
n the viral DNA polymerase gene. ACVR HSV-1 viruses may  have
 deﬁcient TK protein or altered substrate activity.3,4,10,11 More-
ver, the natural hypervariability of the HSV-1 TK gene facilitates
ifferentiation of HSV-1 strains.12,13
. Objectives
The prevalence of intra-ocular ACVR viruses in HSV-1 uveitis
s unknown and may  have clinical consequences. The objective
f this study was to determine the genetic composition and ACV
usceptibility of intra-ocular HSV-1 in herpetic uveitis patients.
dditionally, we determined the cross-resistance of intra-ocular
CVR HSV-1 to ganciclovir (GCV).
. Study design
.1. Clinical specimens
The samples analyzed were surplus intra-ocular ﬂuid (IOF) sam-
les, either aqueous humor or vitreous ﬂuid, obtained from 11
mmunocompetent uveitis patients during diagnostic paracentesis
r therapeutic vitrectomy (patients UV2, UV5 and UV7), respec-
ively (Table 1). HSV-1 was identiﬁed as the causative virus by
eal-time PCR analysis on the respective IOF samples.14 The clini-
al variables scored were age at sampling date, gender, ACV therapy
egimen and clinical picture of ocular disease at presentation and in
he preceding years. No detailed clinical information of patient UV3
as available. The median patient age was 49 years (range 30–69
ears) and 7 patients were female. Eight patients (73%) received
ystemic ACV (n = 4) or valacyclovir (valACV; n = 4) treatment, of
ariable duration (3–52 days, average 15 days), directly before IOF
ample collection (Table 1). Two patients started valACV therapy
fter sample collection (UV3 and UV5). Two patients received com-
lementary topical ACV ointment (UV4 and UV11). All patients
eceived topical corticosteroids at time of sampling. After IOF sam-
le collection, systemic (val)ACV treatment was started, continued
nd/or tapered until the clinical picture improved. None of the
atients received topical or systemic ACV treatment in the 2 years
receding sampling and no patients were treated before or during
ampling with (val)ACV analogues like ganciclovir (GCV). During
ollow-up all patients, except for patient UV7, restored visual acu-
ty to baseline levels (data not shown). Patient UV7 lost vision due
o ocular hypotonia after therapeutic vitrectomy (Table 1). Study
rocedures were performed in compliance with Dutch laws and
nstitutional guidelines and in accordance with the ethical stan-
ards of the Declaration of Helsinki.
.2. HSV-1 thymidine kinase sequence analysis
The entire HSV-1 TK gene was ampliﬁed by PCR using DNA iso-
ated from IOF samples as described.7 From 5 patients (UV6–UV10),
he intra-ocular HSV-1 TK amplicons were directly used for pool
equencing.7 From the remaining 6 HSV-1 uveitis patients, the
ntra-ocular TK gene pool was determined by colony sequencing
s described.12,13 In short, TK amplicons were ligated into the
OPO-TA cloning vector (Invitrogen), transformed into bacteria
nd a variable number of colonies were sequenced. All sequences
ere aligned to a reference HSV-1 TK sequence (strain H129;
enBank: GU734772). A maximum-likelihood phylogenetic tree
f IOF-derived TK nucleotide sequences was estimated under
he general time-reversible model using PhyML 3.0 software.
he IOF-derived HSV-1 TK sequences obtained were deposited inal Virology 57 (2013) 215– 221
GenBank under the accession numbers HQ707581–HQ707642 and
JX392955–JX392980 (Table 2 and Supplementary Table 1).
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.jcv.2013.03.014.
3.3. HSV-1 thymidine kinase functional assay
The functional effect of a selected set of HSV-1 TK variants was
assayed by a described mass spectrometry assay.13 In brief, HSV-
1 TK sequences were cloned into the pcDNA3 expression vector
(Invitrogen) and expressed as recombinant TK proteins in Cos-7
cells. After 48 h of incubation at 37 ◦C, TK protein expression was
determined by ﬂow cytometry using a HSV-1 TK-speciﬁc antibody.
Cell lysates were incubated with 100 M ACV (Sigma–Aldrich)
for 0, 30, 60, and 120 min  at 37 ◦C. Acyclovir and ACVmp levels
were measured in quintuple by MALDI mass spectrometry.13,15
ACV/ACVmp-ratios were corrected for the amount of TK protein
as measured by ﬂow cytometry (data not shown).13 The ACV-
converting activity was normalized to TK activity derived from the
ACV sensitive (ACVS) HSV-1 reference strain KOS,13 which was set
at 100% after 120 min  of incubation. Cut-off value for ACV-resistant
TK variants in the HSV-1 mass spectrometry assay was >10% of the
TK activity of the ACV-sensitive HSV-1 strain KOS.
3.4. In vitro ganciclovir sensitivity testing
Ganciclovir susceptibility assay used was adapted from a recent
study by Shiota et al.16 In short, a human cornea-derived ACV/GCV
cross-resistant HSV-1 strain7 (GenBank: EU541365) was plaque-
puriﬁed in vitro under 50 M ACV and 50 M GCV (Roche)
selection.17 Cloned IOF-derived HSV-1 TK variants were transfected
into Cos-7 cells. After 24 h of incubation at 37 ◦C, transfected cells
were infected with the ACV/GCV cross-resistant HSV-1 clone at a
multiplicity of infection of 0.01. Cells were incubated with 0, 0.1,
0.5, 1, 5, 10, and 50 M of GCV, or solely 50 M ACV, for 18–24 h at
37 ◦C. Cell lysate’s HSV-1 DNA load was determined by real-time
PCR using primers and probes as described.7,18 An ACVS HSV-1
(strain KOS) served as positive control for the efﬁcacy of ACV and
GCV to inhibit HSV-1 replication. Untransfected Cos-7 cells infected
with the ACV/GCV cross-resistant HSV-1 strain served as negative
control. All HSV-1 TK variants were assayed in triplicate.
Median inhibitory concentration (IC50) was  deﬁned as the con-
centration of the antiviral drug that reduced viral DNA copies by
50%. HSV-1 TK variant transfection efﬁciency was checked by TK
protein staining and ﬂow cytometry13 and was always >75% (data
not shown). Relative viral replication was normalized per TK vari-
ant to the viral replication in the absence of antiviral drugs, set at
100%. HSV-1 TK variants were considered ACVR or GCVR if viral
replication levels were >1% in the presence of 50 M ACV and IC50
values ≥1 M GCV,7,18 respectively.
4. Results
4.1. Genetic characteristics of intra-ocular HSV-1 in herpetic
uveitis patients
To gain insight into the incidence and clinical signiﬁcance of
intra-ocular ACVR HSV-1 in HSV-1 uveitis, we determined the
genetic composition and ACV susceptibility of IOF-derived HSV-
1. Intra-ocular HSV-1 was  genotyped by sequencing viral TK
genes in IOF samples from 11 HSV-1 uveitis patients. From 6
IOF samples (UV1–UV5 and UV11), the HSV-1 TK gene was PCR
ampliﬁed, cloned and on average 54 colonies per IOF sample were
sequenced (range 45–74 colonies/sample). From the remaining 5
patients (UV6–UV10), the HSV-1 TK amplicon itself was directly
used for pool sequencing. In total, 88 of 326 (27%) TK nucleotide
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Table 1
Characteristics of patients with herpes simplex virus type 1 (HSV-1) uveitis.
Donor Age; sex Information on preceding ocular disease historya Information on uveitis episode studiedb
Clinical disease Oral or topical ACV Ocular disease Duration disease
before sampling
Time on oral ACV until
sample collection
Total disease
duration
UV1 68; F -3 yrs: Ant. Uveitis No ACV Keratouveitis 57 days 3 days 87 days
UV2  30; M No history ocular
disease
No ACV ARN 28 days 24 days 44 days
UV3  66; F -30 yrs till sampling
date: recurrent Ant
Uveitis eci
No ACV Ant. Uveitis Unknown 0 days Unknown
UV4  62; M -12 yrs: Ant. Uveitis eci No ACV Ant. Uveitis 74 days 52 days 141 days
UV5  62; F -14 yrs: Ant. Uveitis eci No ACV Panuveitis 1 day 0 days 40 days
UV6  39; F -16 yrs: HSV-1 IEK
-14 yrs: keratouveitis
No ACV
No ACV
Keratouveitis 18 days 18 days 41 days
UV7  69; M No history ocular
disease
No ACV ARN 4 days 4 days Vision loss
after 2.5 mth
UV8  41; F -8 yrs: Ant. Uveitis eci
-3 yrs: Ant. Uveitis eci
No ACV
5× 400 mg/day (1
mth)
Ant. Uveitis 3 days 3 days 35 days
UV9  42; F No history ocular
disease
No ACV Ant. Uveitis 20 days 10 days 31 days
UV10  49; F -3 yrs: Ant. Uveitis eci No ACV Ant. Uveitis 28 days 6 days 83 days
UV11  43; M -5 days: stromal
keratitis eci
No ACV Keratouveitis 5 days 0 days 45 days
Abbreviations: UV, uveitis; F, female; M,  male; age, age at time of uveitis episode sampled (years); ACV, acyclovir; ARN, acute retinal necrosis; Ant. Uveitis, anterior uveitis;
eci,  disease of unknown cause; IEK, infectious epithelial keratitis; yrs, years; mth, month.
a Information on history of ocular disease, which preceded the sampled uveitis episode, are indicated. The time point, e.g., “-3yrs: Ant. Uveitis” refers to an episode of
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anterior  uveitis 3 years before the sampled uveitis episode.
b Underlined time intervals indicate patients who  were on valACV treatment. D
resented to the ophthalmologist until resolution of the clinical symptoms.
equences obtained were unique. Eighty-two percent contained
on-synonymous mutations resulting in 72 unique intra-ocular
SV-1 TK protein variants.
Whereas the pool-sequenced IOF samples revealed one patient-
peciﬁc TK protein variant, colony-sequencing identiﬁed 6–26
ifferent HSV-1 TK protein variants per IOF sample (Table 2). One
ajor TK protein variant was identiﬁed in 4 of 5 colony-sequencedOF samples, accounting for on average 72% (range 37–90.5%) of
ll TK protein variants/sample. Except for patients UV1 and UV4,
ll major HSV-1 TK variants were patient-unique at the nucleotide
evel. No minor TK variants were shared between the IOF samples.
able 2
mino acid variation of the predicted herpes simplex virus type 1 (HSV-1) thymidine kina
UV)  patients.
Donor Amino acid changes (percentage of sequenced colonies)
UV1 Major variant: C6G, R41H, Q89R, I138V, A192V, G251C, V
Minor variants: Y4C (1.4); T48M (1.4); R75C (1.4); A152V
UV2  Major variant: Q44H, I138V, S345P (83)
Minor variants: V81I (2.1); A218T, T367A (2.1); Y239C (2.
UV3  Major variant: I138V (85.4)
Minor variants: A152V, A266T (4.2); G200D (2.1); A266V
UV4  Major variant: C6G, R41H, Q89R, I138V, A192V, G251C, V
Minor variants: A2V (2.2); E43G, R226W (2.2); D162N (2.
A375T (6.7)
UV5 Major variant: I138V, G240E (67.9)
Minor variants: A71T, V187M (5.7); A71V (1.9); R106H, A
A207V  (1.9); R220H (1.9); A243V (3.8); L343R (1.9); G356
UV6 S23N, E36K, Q89R, I138V, G240E, R281Q
UV7 I138V, G240E
UV8 D14G, I138V, G240E, C336Y
UV9 I138V, E210D
UV10 Q89R, I138V, M322L
UV11 Mixed population
Major 1: I138V, P173L, G240E (37)
Major 2: Q44H, I138V, S345P (15)
Minor variants: mixture of genetically divergent sequenc
or major variants, the amino acid changes listed are different from the HSV-1 TK refer
mino  acid changes of the donor’s major variant in addition to the listed mutations. Par
mino acid changes. Fs, frameshift and Stop, premature stop codon at the indicated aminn of the sampled uveitis episode was calculated from the ﬁrst clinical symptoms
Notably, IOF-derived HSV-1 TK sequences obtained from patient
UV11 consisted of one dominant and a subdominant TK protein
variant (accounting for 37% and 15% TK nucleotide sequences,
respectively), and 23 minor TK variants (Supplementary Table
1). Pool sequencing of the IOF samples of patients UV1 and UV3
revealed a TK variant identical to the major TK variant identiﬁed
by colony sequencing of the respective sample (data not shown),
demonstrating the applicability of pool sequencing to identify
the dominant TK variant in IOF samples. Phylogenetic analyses
demonstrated that the major and minor TK protein variants
clustered into patient-speciﬁc HSV-1 clades indicating that the
se (TK) protein sequences obtained from intra-ocular ﬂuid samples of HSV-1 uveitis
267L, P268T, D286E, N376H (90.5)
 (1.4); Fs146-182Stop (4.1)
1); R247W, P268S (2.1); L249Q (2.1); P268S (2.1); 281Stop (2.1); G356C (2.1)
 (2.1); M322I (2.1); I326V (2.1); R366H (2.1)
267L, P268T, D286E, N376H (68.9)
2); R216H (4.4); R226W (2.2); A243T, R337W (2.2); G285W (6.7); C362Y (2.2);
152V (1.9); D136N (3.8); A152V (1.9); P173L (1.9); M182T (1.9); L193I (1.9);
C (1.9)
es (see Supplementary Table 1)
ence sequence (GU734772). Minor variants represent sequences that contain the
enthetical values represent percentage of colonies per sample with the respective
o acid position.
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Fig. 1. Phylogenetic tree of intra-ocular HSV-1 TK variants in HSV-1 uveitis patients. A maximum likelihood unrooted tree was estimated under the general time-reversible
model using PhyML software 3.0. HSV-1 TK variants shown are coded by the corresponding HSV-1 uveitis patient (UV1–UV11) and the amino acid change compared with
the  cognate major HSV-1 TK variant (see Table 2; e.g., A152V, alanine at amino acid position 152 changed to valine). In case of patients UV6–UV10 only one HSV-1 TK
s he TK
b
a
v
a
T
t
t
a
aequence was obtained by pool sequencing of the intra-ocular ﬂuid-derived DNA. T
ar  represents number of nucleotide substitutions per site.
ffected eyes contained a mixture of genetically related HSV-1
iruses (Fig. 1). HSV-1 TK quasispecies in patient UV11 contained
 mixed TK variant spectrum genetically related to either major
K variant (Supplementary Table 1 and Fig. 1).
Locations of ACVS- and ACVR-associated polymorphisms withinhe HSV-1 TK protein have been described.3,4,9–11,13,19–26 Among
he 76 unique IOF-derived TK polymorphisms detected, 17 (22%)
nd 9 (12%) residue changes have been reported earlier to confer
n ACVS and ACVR phenotype of the corresponding HSV-1 strain, variants of patient UV11 are numbered according to Supplementary Table 1. Scale
respectively3,4,9–11,13,19–26 and 48 new HSV-1 TK polymorphisms
were identiﬁed (Table 2 and Supplementary Table 1).
4.2. Functional characteristics of intra-ocular HSV-1 TK variants
from herpetic uveitis patientsTo validate the predicted ACVS and ACVR phenotype of IOF-
derived HSV-1 TK variants, the ability of a selected set of TK variants
to convert ACV to ACVmp was  determined by mass spectrometry.13
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Fig. 2. Functional characteristics of intra-ocular HSV-1 TK variants in HSV-1 uveitis patients. Kinetics of the (acyclovir) ACV-converting activity of a subset of HSV-1 TK
variants from 10 HSV-1 uveitis patients (UV1–UV5 and UV7–11) was measured by mass spectrometry. Dominant TK variant is referred to as ‘major’ (Table 2). The minor TK
variants  represent amino acid substitutions at the indicated positions that differ from the major TK variants of the respective uveitis patient. UV11 major I and II represent
the  two  dominant TK variants identiﬁed in the sample of uveitis patient 11. The minor TK variants of patient UV11 are numbered according to Supplementary Table 1. Values
are  calculated from at least 2 independent experiments and are expressed as percentages normalized to data obtained using the TK variant from the ACV-sensitive HSV-1
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10%  of the TK activity of HSV-1 strain KOS. Values are expressed as means ± stand
our of 11 IOF-derived major TK variants, R41H (UV1 and UV4),
336Y (UV8) and P173L (UV11), were deﬁcient to convert ACV
nto ACVmp, conﬁrming the predictive ACVR phenotype of the
orresponding HSV-1 strain (Table 2 and Fig. 2). Furthermore,
everal previously described ACVS-associated (e.g.. Q44H, Q89R,
138V, G240E, and S345P) and ACVR-associated (182Stop, P173L,
216H, R220H, and C336Y) TK polymorphisms were functionally
onﬁrmed.4,9–11,13,19–26 Notably, three newly identiﬁed TK poly-
orphisms (E210D, P268S and M322L) did not alter TK function
Table 2 and Fig. 2).
Next, we tested the susceptibility of the TK variants to GCV,
n alternative TK-dependent antiviral drug commonly used in
reat herpetic eye diseases.27–30 The inhibitory effect of GCV was
ssessed by measuring replication of an ACV/GCV cross-resistant
SV-1 strain in transfected cells expressing recombinant IOF-
erived HSV-1 TK variants. Ganciclovir inhibited all 5 dominant
ntra-ocular ACVS TK variants (patients UV2, UV3, UV5, UV7, UV9
nd UV10) efﬁciently in a dose-response fashion. However, 3 of
 dominant IOF-derived ACVR HSV-1 TK variants obtained from
atients UV1, UV4 and UV11 were cross-resistant to GCV (Table 2
nd Fig. 3).
. Discussion
The plaque reduction assay is considered the gold standard to
etermine the ACV susceptibility proﬁle of HSV-1 isolates.31 The
lternative and more rapid approach is to sequence the HSV-1 TK
ene directly from clinical specimens. This, because ACVR is largely
ttributed to a mutated viral TK gene and multiple ACVR-associated
K polymorphisms have been documented.3,4,9–11,13,19–26 The lat-
er approach is of particular interest for diseases like HSV-1
ncephalitis and uveitis where no infectious virus can be recov-
red from clinical specimens.14,32,33 Besides its potential diagnostic
alue, the hypervariability of the HSV-1 TK gene provides insight
nto the genetic composition of HSV-1 isolates.12,13
We  demonstrated that IOF samples from HSV-1 uveitis patients
ere commonly composed of a patient-speciﬁc HSV-1 quasis-
ecies, consisting of one major HSV-1 TK variant and multiple
enetically related minor TK variants (Fig. 2). These data, along
ith the patients’ positive HSV-1 serostatus, suggest that uveitis
as due to reactivation of one endogenous HSV-1 strain from the
atient’s trigeminal ganglion (TG).34 The minor TK variants may
ave emerged spontaneously, due to ACV therapy or may  have
o-reactivated from the innervating TG. The analogous presence
f multiple genetically related minor and one major TK variant in-off value for ACV-resistant TK variants in the HSV-1 mass spectrometry assay was
ror. 182Stop, premature stop codon at residue 182 of the TK protein.
HSV-1 latently infected human TG supports the latter hypothesis.13
The two genetically different HSV-1 TK clades in the IOF sample of
patient UV11 suggest that the patient’s eye was infected with two
different strains (Supplementary Table 1).
ACVR-associated HSV-1 TK polymorphisms are predominantly
located in 5 regions conserved among Herpesviridae (residues
83–88, 162–164, 216–222, and 284–289), the ATP (residues 51–63)
and nucleoside binding site (residues 168–176), and the highly con-
served cysteine residue at position 336 of the TK protein.4,11,20,23,39
Natural TK polymorphisms, referred to as ACVS-associated muta-
tions, are dispersed throughout the TK. Sequence analysis predicted
that 4 (6%) and 37 (51%) of 72 unique IOF-derived TK variants had
an ACVS and ACVR phenotype, respectively (Table 2 and Supple-
mentary Table 1).13,19,20,22–26 We identiﬁed 48 novel TK protein
polymorphisms resulting in 31 unique intra-ocular TK variants with
an indeﬁnite ACV susceptibility proﬁle. Four of these newly iden-
tiﬁed TK polymorphisms were located in the conserved regions
(D162N, R216L, A218T and G285W) suggesting that that these
residues affect TK protein function. Two of these polymorphisms
(i.e., D162N and R216L) are located at TK residues that with other
amino acid changes (i.e., D162A, R216C and R216H) conferred ACVR
HSV-1.10,35–37 Additionally, three (i.e., A168V, L178P and A207T)
and four (i.e., A243V, A243T, P268S and P274S) are located at TK
residues that with other amino acid changes conferred an ACVR (i.e.,
A168T, L178R and A207P)7,38,39 or ACVS HSV-1 (i.e., A243S, P268T
and P274T),9,22,24,35,36,39 respectively. Overall, HSV-1 TK sequence
comparisons with previously described TK genotypes with con-
ﬁrmed ACV susceptibility suggest an ACVR and ACVS phenotype of
HSV-1 viruses that contain 5 and 4 of the 48 novel HSV-1 TK poly-
morphisms, respectively. Mass spectrometry analysis of a selected
set of IOF-derived TK variants conﬁrmed their predicted ACV sus-
ceptibility proﬁle and provided novel insight into the functional
role of the R41H and 3 novel TK polymorphisms (Fig. 2). Three
newly identiﬁed TK mutations E210D, P268S and M322L did not
affect TK activity demonstrating that they are natural TK poly-
morphisms. The R41H polymorphism, expressed by the major TK
variants of patients UV1 and UV4, has mainly been associated with
ACV-sensitive HSV-1 phenotypes.9,36,37,39,40 In this study, how-
ever, we  demonstrated that an R41H TK variant was  unable to
convert ACV into ACVmp, and the introduction of this HSV-1 TK
variant in an ACV/GCV-resistant HSV-1 strain preserved the antivi-
ral cross-resistant phenotype in vitro, suggesting that R41H is an
ACVR-associated polymorphism in the experimental setting of the
current study (Figs. 2 and 3). The data contrast previous stud-
ies reporting on R41H as a natural TK polymorphism.9,36,37,39,40
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Fig. 3. Ganciclovir sensitivity of intra-ocular HSV-1 TK variants in HSV-1 uveitis patients. The inhibitory effect of increasing concentrations of ganciclovir (GCV), and 50 M
acyclovir (ACV), on viral replication of a GCV/ACV cross-resistant HSV-1 strain in transfected Cos-7 cells expressing intra-ocular ﬂuid-derived HSV-1 TK variants from 9 HSV-1
uveitis  patients (UV2–UV5 and UV7–UV11) was  measured by real-time PCR. Dominant TK variant is referred to as ‘major’ (Table 2). Relative viral replication was normalized
per  TK variant to the viral replication in the absence of antiviral drugs, set at 100%. Values are expressed as means ± standard error. HSV-1 TK variants were considered ACVR
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nr GCVR if viral replication levels were >1% in the presence of 50 M ACV and if IC
0.1  M (i.e., UV2, UV3, UV5, UV7, UV 9 and UV10), 1.2 M (UV4), 0.5 M (UV8) an
xcept for the study by Sauerbrei et al.,40 previous studies on
he R41H polymorphism have combined phenotypic ACV suscep-
ibility and TK genotypic assays on whole virus stocks, but not
irus clones.9,36,37,39 Because clinical isolates and low passage
SV-1 stocks contain multiple virus strains,9,41,42 functional TK
f ACVS viruses in these virus pools may  have compensated for
41H in functional assays to confer an overall ACVS phenotype
f the HSV-1 isolate analyzed. Recently, the signiﬁcance of R41H
as been detailed by expressing the cognate recombinant TK pro-
ein and subsequent determination of the TK enzymatic activity
y an enzyme-linked immunosorbent assay using the thymidine
nalogue bromodeoxyuridine (BrdU) as TK substrate.40 The R41H-
ontaining recombinant TK protein phosphorylated BrdU to values
omparable to the positive control indicating that R41H is a natural
olymorphism.40 Although both BrdU and ACV are substrates for
SV-1 TK, the chemical structures are different and thereby with-
old extrapolation of the enzymatic activity of R41H-containing
K proteins obtained with BrdU to the guanosine analogue ACV
s substrate. Further studies, including ACV susceptibility assays
n both the respective HSV-1 clones and recombinant TK pro-
eins generated by marker rescue experiments, are warranted to
omplement the known set of ACVS- and ACVR-associated TK poly-
orphisms, including the R41H polymorphism, mandatory for a
uccessful implementation of diagnostic HSV-1 TK genotyping in
he clinic.
The proportion of ACVR viruses at the infection site determines
he efﬁcacy of ACV therapy.9,42,43 We  demonstrated that 4 of 10
40%) HSV-1 uveitis clinical isolates tested harbored a dominant
CVR HSV-1 variant, which is higher than expected for immuno-
ompetent individuals.3,6–8 Three of 4 ACVR HSV-1 uveitis patients
eceived no ACV treatment (UV11), or only for 3 days (UV1 and
V8), before IOF sampling suggesting primary ACVR or reactivation
f the corresponding latent ACVR HSV-1.13 Moreover, none of the
atients received topical or systemic ACV treatment in the 2 years
receding sampling. Overall, the ACV susceptibility proﬁle of intra-
cular HSV-1 did not correlate with symptomatic ACV treatment
uring or preceding the uveitis episode sampled. Given the het-
rogeneous patient group with different uveitis entities, different
umbers of disease episodes prior to moment of sampling, differentues ≥1 M GCV, respectively. The GCV IC50 values for the tested TK variants were
 M GCV (UV11).
antiviral treatment strategies and ways of application, no correla-
tion between intra-ocular ACVR HSV-1 and disease outcome could
be made. A future study on a larger and more homogenous group
of ACV (non-)treated HSV-1 uveitis patients is warranted to deter-
mine the association between ACVR HSV-1 and clinical outcome.
Moreover, when ACV treatment fails or is poorly tolerated, other
nucleoside analogues like GCV are optional to treat herpetic eye
diseases.27–30 GCV is also a HSV-1 TK-dependent antiviral posing
the risk of ACV/GCV-cross-resistance.4,44 Indeed, 3 of 4 dominant
IOF-derived ACVR TK variants were cross-resistant to GCV. Patient
UV8, however, who had a dominant intra-ocular ACVR/GCVS TK
variant would have beneﬁtted from a switch to GCV treatment.
Patients UV1, UV4 and UV11, with a dominant ACV/GCV-cross-
resistant HSV-1 TK variant, should have preferably been treated
with TK-independent drugs like foscarnet.31
To the best of our knowledge, this is the ﬁrst study reporting
on the presence of HSV-1 quasispecies and the relative high preva-
lence of ACVR HSV-1 in IOF samples of immunocompetent HSV-1
uveitis patients. The data justify further studies on the prevalence
and role of ACV- and GCV-resistant HSV-1 in relation to clinical
outcome of HSV-1 uveitis. Mapping of ACVR-associated HSV-1 TK
polymorphisms will aid in the development of a diagnostic HSV-1
TK genotyping platform for a rationalized selection of the appro-
priate antiviral drugs to prevent the development of severe ocular
HSV-1 diseases.
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